A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Summary

A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.

Timeline

Start

2023-01-04

Primary completion

2025-01-31

Completion

2025-02-05

Outcome

Outcome not reported

Stopped: “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.”

Drugs

Indications